Literature DB >> 1856736

The effect of zidovudine on chronic myelopathy associated with HTLV-1.

O Gout, A Gessain, M Iba-Zizen, S Kouzan, F Bolgert, G de Thé, O Lyon-Caen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1856736     DOI： 10.1007/bf00315691

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  4 in total

1.  Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation.

Authors:  O Gout; M Baulac; A Gessain; F Semah; F Saal; J Périès; C Cabrol; C Foucault-Fretz; D Laplane; F Sigaux
Journal:  N Engl J Med       Date:  1990-02-08       Impact factor: 91.245

2.  Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I.

Authors:  S Matsushita; H Mitsuya; M S Reitz; S Broder
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

3.  Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy.

Authors:  C L Tendler; S J Greenberg; W A Blattner; A Manns; E Murphy; T Fleisher; B Hanchard; O Morgan; J D Burton; D L Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

4.  High human T-cell lymphotropic virus type I proviral DNA load with polyclonal integration in peripheral blood mononuclear cells of French West Indian, Guianese, and African patients with tropical spastic paraparesis.

Authors:  A Gessain; F Saal; O Gout; M T Daniel; G Flandrin; G de The; J Peries; F Sigaux
Journal:  Blood       Date:  1990-01-15       Impact factor: 22.113
  4 in total
  10 in total

Review 1.  HTLV-1 infections.

Authors:  C R Bangham
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

Review 2.  Tetraspanins in viral infections: a fundamental role in viral biology?

Authors:  F Martin; D M Roth; D A Jans; C W Pouton; L J Partridge; P N Monk; G W Moseley
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 3.  The myeloneuropathies of Jamaica.

Authors:  O St Clair Morgan
Journal:  Mol Neurobiol       Date:  1994 Apr-Jun       Impact factor: 5.590

Review 4.  Pathogenesis and treatment of HTLV-I associated myelopathy.

Authors:  G P Taylor
Journal:  Sex Transm Infect       Date:  1998-10       Impact factor: 3.519

5.  Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy.

Authors:  G P Taylor; S E Hall; S Navarrete; C A Michie; R Davis; A D Witkover; M Rossor; M A Nowak; P Rudge; E Matutes; C R Bangham; J N Weber
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

Review 6.  Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis: toward rational targeted therapy.

Authors:  Unsong Oh; Steven Jacobson
Journal:  Neurol Clin       Date:  2008-08       Impact factor: 3.806

7.  Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial.

Authors:  Graham P Taylor; Peter Goon; Yoshitaka Furukawa; Hannah Green; Anna Barfield; Angelina Mosley; Hirohisa Nose; Abdel Babiker; Peter Rudge; Koichiro Usuku; Mitsuhiro Osame; Charles R M Bangham; Jonathan N Weber
Journal:  Retrovirology       Date:  2006-09-19       Impact factor: 4.602

Review 8.  Antiretroviral Therapy in HTLV-1 Infection: An Updated Overview.

Authors:  Francesca Marino-Merlo; Emanuela Balestrieri; Claudia Matteucci; Antonio Mastino; Sandro Grelli; Beatrice Macchi
Journal:  Pathogens       Date:  2020-05-01

Review 9.  Co-Infection and Cancer: Host-Pathogen Interaction between Dendritic Cells and HIV-1, HTLV-1, and Other Oncogenic Viruses.

Authors:  Tania H Mulherkar; Daniel Joseph Gómez; Grace Sandel; Pooja Jain
Journal:  Viruses       Date:  2022-09-14       Impact factor: 5.818

10.  Human T-lymphotropic virus 1 neurologic disease.

Authors:  Abelardo Araújo; Marco Antonio Lima; Marcus Tulius T Silva
Journal:  Curr Treat Options Neurol       Date:  2008-05       Impact factor: 3.972
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.